Valuation: Pulmonx Corporation

Market Cap 68.85M 59.85M 55.71M 51.14M 96.58M 6.57B 98.08M 657M 258M 3.27B 259M 253M 10.97B P/E 2026 *
-1.58x
P/E 2027 * -1.71x
Enterprise Value 68.85M 59.85M 55.71M 51.14M 96.58M 6.57B 98.08M 657M 258M 3.27B 259M 253M 10.97B EV / Sales 2026 *
0.76x
EV / Sales 2027 * 0.7x
Free-Float
95.11%
Yield 2026 *
-
Yield 2027 * -
1 day+1.24%
1 week+33.61%
Current month+25.38%
1 month+25.38%
3 months+27.34%
6 months-0.61%
Current year-26.24%
1 week 1.18
Extreme 1.18
1.85
1 month 1.17
Extreme 1.17
1.85
Current year 1.13
Extreme 1.13
2.39
1 year 1.13
Extreme 1.13
2.89
3 years 1.13
Extreme 1.13
14.84
5 years 1.13
Extreme 1.13
45.49
10 years 1.13
Extreme 1.13
69.48
Manager TitleAgeSince
Chief Executive Officer 64 2025-10-26
Director of Finance/CFO 53 2019-04-30
Chief Tech/Sci/R&D Officer - 2020-02-29
Director TitleAgeSince
Director/Board Member 72 2007-01-31
Chairman 66 2019-09-30
Director/Board Member 64 2014-12-17
Date Insider Type Main position Quantity % Market Cap.
3/2/26 Sell

Executive/Senior Manager

107,732 0.2612%
12/8/25 Sell

Director

23,321 0.0565%
12/3/25 Other

Chief Technology Officer

358,426 0.8690%
Change 5-day change 1-year change 3-year change Capi.($)
+1.24%+33.61%-48.25%-87.87% 68M
+0.43%+0.77%+27.32%+5.88% 12.58B
+0.55%+3.62%+21.22%+20.51% 6.73B
-0.80%+5.77%+52.21%+24.28% 6.03B
-0.52%+10.53% - - 5.1B
+3.47%+5.88%-20.95%+28.52% 4.59B
+0.32%+2.56%-20.92%-16.97% 4.13B
+0.32%+4.75%-13.93%+225.95% 1.83B
-2.56%-25.76%+35.28%-55.46% 1.77B
+1.27%-0.49%+58.07%-5.60% 1.56B
Average +0.37%+5.26%+10.00%+15.47% 4.44B
Weighted average by Cap. +0.38%+3.09%+18.92%+18.30%

Financials

2026 *2027 *
Net sales 90.55M 78.71M 73.26M 67.27M 127M 8.64B 129M 864M 339M 4.3B 340M 333M 14.43B 98.31M 85.46M 79.55M 73.04M 138M 9.39B 140M 938M 368M 4.67B 369M 361M 15.67B
Net income -43.53M -37.84M -35.22M -32.33M -61.06M -4.16B -62.01M -415M -163M -2.07B -163M -160M -6.94B -40.97M -35.61M -33.15M -30.43M -57.47M -3.91B -58.36M -391M -153M -1.95B -154M -150M -6.53B
Net Debt - -
Logo Pulmonx Corporation
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Employees
296
Date Price Change Volume
26-07-31 US$1.630 +1.24% 1,681,215
26-07-30 US$1.610 +28.80% 4,813,008
26-07-29 US$1.250 -.--% 231,103
26-07-28 US$1.250 +2.46% 246,330
26-07-27 US$1.220 +4.27% 247,364
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.630USD
Average target price
3.400USD
Spread / Average Target
+108.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LUNG Stock